Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
13 papers
Recent·Most cited
N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe
The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.
bioRxiv · Jan 12, 2022Immunology
S. Bangaru, A. Antanasijevic, N. Kose, L. M. Sewall, A. M. Jackson, N. Suryadevara, X. Zhan, J. L. Torres, J. Copps, A. Torrents de la Pena, J. E. Crowe, A. B. Ward
The paper maps epitopes of polyclonal antibodies against beta-coronavirus spike proteins in human sera, revealing cross-reactive patterns between seasonal and SARS-2 infections.
bioRxiv · Sep 30, 2021Immunology
K. J. Kramer, E. M. Wilfong, K. Voss, S. Barone, A. R. Shiakolas, N. Raju, C. E. Roe, N. Suryadevara, L. M. Walker, S. C. Wall, A. Paulo, S. Schaefer, D. Dahunsi, C. S. Westlake, J. E. Crowe, , J. M. Irish
bioRxiv · Jul 28, 2021Immunology
A. R. Shiakolas, N. Johnson, K. J. Kramer, N. Suryadevara, D. Wrapp, S. Periasamy, K. A. Pilewski, N. Raju, R. Nargi, R. E. Sutton, L. Walker, I. Setliff, J. E. Crowe, A. Bukreyev, R. H. Carnahan, , I. S. Georgiev
This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.
bioRxiv · Jun 2, 2021 · PreprintImmunology
K. J. Kramer, N. V. Johnson, A. R. Shiakolas, N. Suryadevara, S. Periasamy, N. Raju, J. K. Williams, D. Wrapp, S. J. Zost, C. M. Holt, C.-L. Hsieh, R. E. Sutton, A. Paulo, E. Davidson, B. J. Doranz, , I. S. Georgiev
This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.
bioRxiv · May 16, 2021Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe
The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.
bioRxiv · May 2, 2021Immunology
P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe
This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.
bioRxiv · May 2, 2021 · PreprintImmunology
N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe
The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.
bioRxiv · Jan 19, 2021Immunology
S. J. Zost, J. Dong, I. M. Gilchuk, P. Gilchuk, N. J. Thornburg, S. Bangaru, N. Kose, J. A. Finn, R. Bombardi, C. Soto, R. S. Nargi, R. P. Irving, N. Suryadevara, J. B. Westover, R. H. Carnahan, , J. E. Crowe
The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.
bioRxiv · Dec 31, 2020Immunology
A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev
The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.
bioRxiv · Dec 20, 2020 · PreprintImmunology
A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom
This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.
bioRxiv · Sep 10, 2020Microbiology
S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe
The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.
bioRxiv · May 22, 2020Immunology
S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe
This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.
bioRxiv · May 12, 2020Immunology